RLMD NASDAQ
Relmada Therapeutics, Inc.
1W: -5.6%
1M: -4.6%
3M: +72.3%
YTD: +60.9%
1Y: +1425.0%
3Y: +846.8%
5Y: +4.6%
$7.05
+0.02 (+0.28%)
Weekly Expected Move ±7.0%
$6
$6
$7
$7
$8
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$0.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$515.5M
52W Range0.48-8
Volume1,449,894
Avg Volume1,881,719
Beta0.43
Dividend—
Analyst Ratings
Company Info
CEOSergio Traversa
Employees17
SectorHealthcare
IndustryBiotechnology
IPO Date2014-06-20
Websiterelmada.com
2222 Ponce de Leon Boulevard
Coral Gables, FL 33134
US
Coral Gables, FL 33134
US
786 629 1376
About Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Latest News
Relmada targets mid-2026 Phase 3 RESCUE start backed by $234M cash runway through 2029
Earnings Scheduled For May 12, 2026
Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives $12.00 Consensus Target Price from Analysts
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| TRAVERSA SERGIO | P-Purchase | 27,500 | $4.12 | 2025-12-15 |
| Shenouda Maged | P-Purchase | 11,665 | $4.12 | 2025-12-15 |
| TRAVERSA SERGIO | A-Award | 1,198,000 | $4.06 | 2025-12-12 |
| Shenouda Maged | A-Award | 828,000 | $4.06 | 2025-12-12 |
| Ence Chuck | A-Award | 828,000 | $4.06 | 2025-12-12 |